This phase II trial (NCT01666444) investigated the combination of the toll-like receptor 8 (TLR8) agonist motolimod with ICD-inducing chemotherapeutic pegylated liposomal doxorubicin in women with recurrent or persistent ovarian cancer. The gene discussed is TLR8; the disease is ovarian carcinoma.